Cevira

{{Update|clinical trial phase III|date=September 2016}}

{{UDP|date=June 2019}}

Cevira is in development as a local treatment for Cervical intraepithelial neoplasia lesions and human papilloma virus (HPV) of the cervix without damaging healthy tissue. With Cevira, Photocure aims to develop the first non-surgical treatment for precancerous cervical lesions using photodynamic therapy (PDT). Cevira treatment is administered locally and remains in contact with the cervix to deliver treatment for up to 24 hours. A cup holds the ointment against the cervix for initial absorption. After a few hours, a light source within the cup emits light at a specific wavelength so the Active Pharmaceutical Ingredient, hexylaminolevulinate (HAL), reacts with the tissue.{{cite web | url=http://www.medicaldevice-network.com/news/news113548.html/ | title=Photodynamic Device Developed to Treat Precancerous Cervical Lesions | publisher=Medical Advice Network | date=18 March 2011 | accessdate=2013-06-06}}{{cite web | url=http://www.mddionline.com/article/drug-and-light-join-forces-fight-precancerous-lesions | title=Drug and Light Join Forces to Fight Precancerous Lesions | publisher=MDDI | date=April 18, 2011 | accessdate=2013-06-06 | author=Fontanazza, Maria | archive-url=https://web.archive.org/web/20130414084537/http://www.mddionline.com/article/drug-and-light-join-forces-fight-precancerous-lesions | archive-date=April 14, 2013 | url-status=dead }}